This study was developed to evaluate efficacy and safety of belzutifan plus TKI lenvatinib versus TKI cabozantinib in patients with advanced RCC progressing after anti-PD-1/PD-L1 therapy in the first- or second line setting or as an adjuvant therapy. This evidence concerns the gene PDCD1 and renal cell carcinoma.